CSL Reports Significant Profit Growth Fueled by Biotherapeutics and Plasma Collection
Monday, 12 August 2024, 19:23
CSL Reports 25% Profit Increase
Biotherapeutics giant CSL (ASX: CSL) has released its latest financial results, showcasing a substantial growth in net profit.
Financial Performance Highlights
- Net profit after tax reached US$2.64 billion for the fiscal year ending 30 June.
- This marks a 25% increase over last year’s figures when adjusted for constant currency.
- The growth is primarily driven by robust sales in immunoglobulins and enhanced plasma collection initiatives.
Conclusion
CSL's continued focus on biotherapeutics and its commitment to improving operational efficiencies indicate a bright future for the company and its stakeholders.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.